In the double-blind placebo-controlled Phase 3 TRANSFORM-1 study, the investigational medication (navitoclax) in combination with ruxolitinib will be compared to ruxolitinib with matching placebo, to evaluate its effect on splenomegaly, bone marrow fibrosis, anemia responses and quality of life.
Navitoclax, an investigational agent, is under clinical development and is not approved by regulatory health authorities. Safety and efficacy are under evaluation.
ClinicalTrials.gov Identifier: NCT04472598
EudraCT Number: 2020-000097-15